Join
Live feed
·
PRReleasevia Quantisnow
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
VRCA· Verrica Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VRCA (Verrica Pharmaceuticals Inc.) and more on Quantisnow.